Pricing

Five things for pharma marketers to know: Wednesday, September 27, 2017

Five things for pharma marketers to know: Wednesday, September 27, 2017

By

AbbVie adds context to CEO's comments on drug pricing; Pandora makes a play for pharma ad dollars; shortages expected of drugs manufactured in Puerto Rico

Five things for pharma marketers to know: Tuesday, September 26, 2017

Five things for pharma marketers to know: Tuesday, September 26, 2017

By

Patient assistance nonprofit contacted in Aegerion probe; most heavily marketed drugs in Canada offer little therapeutic value; the FDA pans Duchenne drug

Five things for pharma marketers to know: Wednesday, September 13, 2017

Five things for pharma marketers to know: Wednesday, September 13, 2017

By

FDA closes pediatric study loophole; little evidence outcomes-based contracts are working; PBMs lobby against transparency efforts

Snubbing Intolerance: Frazier's Path Was Disengagement

Snubbing Intolerance: Frazier's Path Was Disengagement

By

Merck CEO Kenneth Frazier's exit from a presidential manufacturing council may go down as one of the most principled stands by the CEO of a major U.S. company, let alone a drugmaker.

Five things for pharma marketers to know: Thursday, August 31, 2017

Five things for pharma marketers to know: Thursday, August 31, 2017

By

Pfizer develops Minecraft version for kids with hemophilia; Lilly to resubmit baricitinib to the FDA; pricing expert says Novartis CAR-T value contract is 'progress'

Five things for pharma marketers to know: Wednesday, August 30, 2017

Five things for pharma marketers to know: Wednesday, August 30, 2017

By

Nonprofits receive FDA approval for Chagas drug; Gilead's buyout of Kite will put it back in pricing fray; most cancer patients don't receive fertility info

Five things for pharma marketers to know: Wednesday, August 23, 2017

Five things for pharma marketers to know: Wednesday, August 23, 2017

By

Doctors fret about price of Novartis' experimental CAR-T therapy; study finds digital pillboxes don't improve adherence; India awards Pfizer vaccine patent

Five things for pharma marketers to know: Friday, August 18, 2017

Five things for pharma marketers to know: Friday, August 18, 2017

By

Lawmakers to investigate pricing of MS drugs; Mylan will pay $465 million to resolve EpiPen allegations; the FDA approves Pfizer's new cancer drug

Study: Hiking the prices of heart drugs led to fewer sales

Study: Hiking the prices of heart drugs led to fewer sales

By

Prescription rates dramatically decreased following the price hikes of Valeant's Isuprel and Nitropress in 47 hospitals.

Five things for pharma marketers to know: Wednesday, August 16, 2017

Five things for pharma marketers to know: Wednesday, August 16, 2017

By

Gottlieb criticizes drugmakers for 'gaming the system' on generics; investors ignore Trump's pharma criticism; docs are more supportive of single payer

Frazier's call earns him praise, rare for a pharma CEO

Frazier's call earns him praise, rare for a pharma CEO

By

It's not often that pharmaceutical companies are held up as examples of morality or leadership to the general public.

Questions About Promotion Prompt Marketers to Develop Code of Ethics

Questions About Promotion Prompt Marketers to Develop Code of Ethics

That's why the Coalition for Healthcare Communication is focused on creating self-regulatory guidelines.

Biogen, Merck use predictive modeling to better negotiate value-based contracts

Biogen, Merck use predictive modeling to better negotiate value-based contracts

By

What's holding back value-based pricing deals from moving beyond the pilot phase?

Bill to allow imported drugs from Canada aims to create competition

Bill to allow imported drugs from Canada aims to create competition

By

The Congressional Budget Office says that Sanders' bill would save the U.S. federal government nearly $7 billion over the next decade.

On Shkreli, Here Are the Lessons for Pharma to Learn and Apply

On Shkreli, Here Are the Lessons for Pharma to Learn and Apply

Though Shkreli may soon slip from the public eye, separated from his Twitter account and prohibited from trading securities, pharma communicators must learn from these events.

Five things for pharma marketers to know: Monday, July 24, 2017

Five things for pharma marketers to know: Monday, July 24, 2017

By

Samsung Bioepis launches Remicade biosimilar; WHO encourages uses of generic version of Sovaldi; nearly 20 million people with HIV on treatment

Five things for pharma marketers to know: Tuesday, July 11, 2017

Five things for pharma marketers to know: Tuesday, July 11, 2017

By

Trump administration considers outcomes-based approach to lower drug prices; Sanofi to acquire vaccines biotech; Nestle partners with Enterome to develop microbiome-based diagnostics

Five things for pharma marketers to know: Monday, June 26, 2017

Five things for pharma marketers to know: Monday, June 26, 2017

By

The performance of generic drugs is not always guaranteed; the FDA approves a new blood thinner; Gottlieb wants rejection letters public

Five things for pharma marketers to know: Wednesday, June 21, 2017

Five things for pharma marketers to know: Wednesday, June 21, 2017

By

Insurance companies balk at expensive PCSK9 inhibitors; Publicis to focus investments on AI platform; clinical trial reveals Novartis' eye drug requires less frequent injections

Five things for pharma marketers to know: Friday, June 16, 2017

Five things for pharma marketers to know: Friday, June 16, 2017

By

Apple reportedly working to bring EMRs to iPhone; FDA to study disclosures in ads; Trump admin discussing drug price EO

Five things for pharma marketers to know: Friday, June 9, 2017

Five things for pharma marketers to know: Friday, June 9, 2017

By

The FDA asks Endo to take opioid off the market; Lilly partners with Swiss biotech; House committee advances PDUFA bill — without off-label provision

Physicians call for DTC ads to include retail prices

Physicians call for DTC ads to include retail prices

By

They are asking the American Medical Association to support the policy proposal.

Five things for pharma marketers to know: Monday, June 5, 2017

Five things for pharma marketers to know: Monday, June 5, 2017

By

Medicare beneficiaries struggle to pay for COPD inhalers; Novartis partners with IBM Watson Health; Mylan hasn't lowered EpiPen prices

Five things for pharma marketers to know: Thursday, June 1, 2017

Five things for pharma marketers to know: Thursday, June 1, 2017

By

50% of consumers say they will share their health data with tech giants; pharma CEOs expect pricing proposal from Trump administration; FDA approves generic versions of Strattera

Keep Calm and Sell Drugs: Your New Daily Affirmation?

Keep Calm and Sell Drugs: Your New Daily Affirmation?

By

To be sure, anything borrowing from the well-known "Keep Calm" genre should not be construed as advice. The doctor is definitely not in.

In Surprising Twist, Trust Rises for Healthcare Companies

In Surprising Twist, Trust Rises for Healthcare Companies

But will pharma and biotechnology firms be able to advance this year's positive momentum?

Five things for pharma marketers to know: Tuesday, May 9, 2017

Five things for pharma marketers to know: Tuesday, May 9, 2017

By

Sanofi ties price increases to growth rate; Regeneron to target 7,000 docs on new eczema drug Dupixent; NIH and biotech execs meet White House officials

Five things for pharma marketers to know: Monday, May 8, 2017

Five things for pharma marketers to know: Monday, May 8, 2017

By

Pfizer to provide Ibrance for free during NICE analysis; the FDA approves new ALS drug; people turn to Twitter to tell stories about pre-existing conditions

Five things for pharma marketers to know: Thursday, May 4, 2017

Five things for pharma marketers to know: Thursday, May 4, 2017

By

Louisiana may use 1910 law to discount hep-C drugs; House bill would reduce coverage for 24 million people; drugmakers pursue pay-for-performance deals

U.S. drug spend grew by 6% in 2016, the lowest rate in two years

U.S. drug spend grew by 6% in 2016, the lowest rate in two years

By

This is likely due to fewer product launches and lower price increases.